Answers are grounded in this paper and cite their sources.
Despite concerted efforts to increase deceased donation, very little progress has been made over the past decade (1). Significant gains in closing the gap between organ supply and demand in kidney transplantation are likely to come from increasing live donation. One of the most significant barriers to optimization of live kidney donation is ABO incompatibility (ABOi). Based on blood group frequencies in the United States, there is a 36% probability that any two individuals will be ABOi, eliminating up to one-third of the potential live donor pool. ABO incompatibility has been considered an absolute contraindication to transplantation due to an unacceptably high risk of hyperacute or acute antibody-mediated rejection and early allograft loss (2). Fueled by the deepening crisis in organ availability, there has been renewed interest in crossing the ABO blood group barrier in live donor transplantation. The article by Schwartz et al. provides a thorough review of the results from one of the North American leaders in ABOi transplantation with special emphasis on the cost, resource utilization, and complications encountered in protocols used to precondition patients to receive a blood type incompatible kidney (3). Not surprisingly, preconditioning adds significantly to the cost (US$38,000/case) of the transplant episode but is cost effective when compared to dialysis. Currently most insurers do not have separate payment rates for compatible and incompatible live donor transplants, which places the providers at financial risk, tempering enthusiasm for these procedures. However, there are examples of recent developments in transplantation that have been largely patient driven (e.g., laparoscopic donor nephrectomy) and as waiting times increase, patients will likely demand access to ABOi protocols. In this article, we will explore the promise and limitations of new options that exist for patients with incompatible live donors. Although ABOi transplantation was once considered a high-risk procedure, recent results are comparable to blood type compatible live donor outcomes (4–7). We have transplanted 39 patients with live donor kidneys across a blood group barrier with a 95% graft survival rate at a mean follow up of 2 years. The use of mycophenolate mofetil (MMF) in preconditioning regimens, posttransplant plasmapheresis, and isoagglutinin monitoring have been offered as possible explanations for the dramatic change in ABOi graft survival that has occurred in recent years. Splenectomy, once thought to be the sine qua non of ABOi transplantation, represents a major disincentive to wider adoption of ABOi protocols (8). Several small series have demonstrated that anti-CD20 can be substituted for splenectomy with good results (9, 10). While the concept of a temporary B-cell ablative therapy is attractive, this is an off label use of anti-CD20 and most insurers have not paid for it. We have now performed 13 ABOi transplants without splenectomy or anti-CD20 (11). These patients have been preconditioned with plasmapheresis/low dose IVIg, daclizumab, and standard triple immunosuppression. The series includes A1 and AB donors into O recipients and titers as high as 512. All grafts are functioning and this is now our standard approach to ABOi transplants. Elimination of splenectomy (US$2,250) and anti-CD20 (US$5,000) would be predicted to reduce surgical and infectious complications as well as reducing the cost of therapy. Kidney paired donation (KPD) is an alternative for some patients who have incompatible donors. Paired donation involves the matching of two or more incompatible donor/recipient pairs such that compatible transplants are achieved for all recipients (12). The most common blood type incompatibility is an A donor and an O recipient. KPD has limited capability in producing a pairing for this blood group combination because of the requirement for an O donor. List paired donation (LPD) is another solution that involves the donor of an incompatible pair giving a kidney to a patient at the top of the deceased donor waiting list in order to elevate their intended recipient’s status on the list (13). LPD has been challenged on ethical grounds because it results in an exodus of O kidneys from the list, further disadvantaging an already vulnerable population (14). Ethical concerns as well as the observation that it would provide little additional benefit to live donor KPD make LPD unlikely to gain wide acceptance (Fig. 1) (15).FIGURE 1.: An integrated national approach to incompatible live donor pairs. Using simulated populations we have estimated that between 2,500 and 4,000 incompatible pairs (ABO incompatible and positive crossmatch) would be available to enter a national Kidney Paired Donation (KPD) pool in the United States each year. A mathematically optimized algorithm could match 47% of the pool in the first match run. The remaining 53% could reenter the next match run with new registrants but have already identified themselves as being hard-to-match and would have a lower probability of being successful. These patients could be placed into a List Paired Donation (LPD) pool but with the ethical restrictions that have been suggested (blood type O recipients with non-O donors and recipients with PRA >80% would be excluded) only 4% of them could be expected to be transplanted by LPD. This small gain may not justify the use of LPD if a national live donor KPD list is created. The remaining unmatched patients would be considered for desensitization. A portion of these patients would not be candidates for desensitization due to prohibitively high titer DSA or immunologic risk with their intended donors. These patients could enter a second KPD pool the purpose of which is to identify a donor amenable to desensitization.KPD and desensitization have developed along parallel tracks without much consideration of the intersection between the two modalities (12, 16). Figure 1 depicts how these approaches might be integrated in the future. Using optimized mathematical modeling and simulated populations of donors and recipients, our group has shown that a pool of incompatible patients of the size predicted on a national scale (2500–4000 new registrants per year) could achieve a match rate of 47% (17). While there would be administrative expenses for the oversight of a national KPD system, these are estimated to be considerably less costly than desensitization and dramatically less than dialysis (17). The 53% that are predicted to go unmatched are largely patients with hard-to-match blood type combinations and broadly sensitized patients. Although the possibility of locating a pairing in the next KPD match run exists, the likelihood remains low leading to the accumulation of these patients in the pool (18). Patients that do not match in KPD but have blood group and HLA reactivity that is amenable to desensitization are removed from the pool and desensitized to their donor (19). After multiple match runs, 85% of our single center KPD registrant pool is now highly sensitized with high titer HLA reactivity and the remainder consists mostly of O recipients and AB donors as was predicted from our simulations. For this reason we have relaxed our matching criteria and now consider a low titer positive crossmatch or ABO incompatibility as acceptable. In other words, the goal of the pairings is not necessarily to achieve a negative crossmatch or ABO compatibility but rather to identify a better immunologic match, one that would require less desensitization (12). The concept of paired kidney matching in order to reduce desensitization requirements is a new one and should considerably reduce the overall costs for patients with high DSA titers. Difficult-to-match patients who present with an incompatible live donor should no longer be relegated to joining the ever-expanding deceased donor queue. There are now several options available that can enable them to be successfully transplanted. In the future, a better understanding of risk and more refined methods of predicting crossmatch results and waiting times will allow the clinicians to choose the optimal therapeutic modality for their patient’s unique immunologic challenges, saving lives and hundreds of millions in health care dollars.
No takes yet. Share an insight, caveat, or question.
Montgomery et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: